Device Trial Radar · NCT06009458
Acuity 200™ (Fluoroxyfocon A) Orthokeratology Contact Lens for Overnight Wear
Last checked: Nov 19, 2026Latest source record: Jan 14, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
387
Actual
Start
Oct 1, 2023
Primary completion
Sep 2025
Study completion Sep 2025
Sponsor
- Lead sponsor
- Acuity Polymers, Inc.Not on our public-company list
- Sponsor type
- Industry
- First posted
- Aug 24, 2023
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 7 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The objective of this clinical investigation is to collect scientifically valid safety and effectiveness data on the Acuity 200™ (fluoroxyfocon A) Orthokeratology Contact Lens for Overnight Wear. The clinical performance data reported from this study is intended to be submitted to the U.S. Food and Drug Administration Center for Devices and Radiological Health (CDRH) in support of a new Premarket Application (PMA).
Conditions
- Myopia
Interventions
Acuity 200™ (fluoroxyfocon A) Orthokeratology Contact Lens for Overnight WearDevice
Acuity 200™ Orthokeratology Contact Lenses are intended to be worn overnight with removal during following day. The lenses are designed to produce a temporary reduction of myopia by reversibly altering the curvature of the cornea. The lenses are manufactured from fluoroxyfocon A, which is a gas permeable contact lens material composed of a siloxanyl fluoromethacrylate copolymer. The material name fluoroxyfocon A is registered with United States Adopted Name (USAN).The Acuity 200™ (fluoroxyfocon A) Orthokeratology Contact Lens is available in spherical, asymmetrical, aspheric, and tangential lens designs to best fit the individual cornea, using corneal topography and/or diagnostic lenses.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Lines of improvement of monocular UCVA at the 12-month visit (overall and stratified by baseline sphere)Time frame: 1 year
- Attempted vs. Achieved Reduction in manifest refractive errorTime frame: 1 Year
- Proportion of eyes achieved UCVA of ≤0.30 logMAR , ≤0.20 logMAR ,≤0.10 logMAR, and ≤0.00 logMARTime frame: 1 Year
5 more outcomes with a free account
Locations
13 sites in 3 countries. Site status is shown where the registry gives one.
Advanced Optometry of Mission Viejo
Mission Viejo, California
Elsa Pao, O.D. Optometrist
Oakland, California
Pacific Rims Optometry
San Francisco, California
10 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.